Speaker Profile
Ph.D., CEO, Sansimeon
Biography
Phil leads the development of Sansimeons sample to answer single cell platform, bringing together automated sample preparation and scalable sequencing to enable reproducible, large-scale cellular datasets for AI-driven drug discovery and translational research. Before starting Sansimeon, he helped bring three commercial single cell sequencing systems to market at BD Biosciences, working across software, hardware, and fluidics to make these platforms more robust and easier to use. Earlier, at Massachusetts General Hospital, he directed engineering initiatives to scale a microfluidic system for isolating circulating tumor cells from whole blood, supporting advances in oncology and liquid biopsy research. Phil has spent his career building tools that solve practical bottlenecks in translational science, in particular for applications in oncology.
Talk
Solving the Multiomics Reproducibility Bottleneck for AI Discovery
Current single-cell workflows are limited by manual and variable sample preparation that undermines reproducibility, cell recovery, and scalability. This prevents researchers from generating consistent and AI-ready datasets. Sansimeon addresses this gap with an automated turnkey platform that standardizes preparation and integrates scalable sequencing to enable reliable large-scale single-cell analysis for translational and drug discovery applications.
Spatial Showcase:
Sansimeon
Sansimeon is a life science tools company building next-generation single cell sequencing platforms that remove the technical bottlenecks limiting clinical and translational research. Our technology produces scalable, high fidelity single cell multiomic datasets that enable reproducible science and support advanced computational analysis, including machine learning models for drug discovery, immunotherapy, and precision medicine.
